The new US-based centre will include the construction of purpose-built cleanroom suites
Phillips-Medisize, a Molex company, is expanding the capabilities of the 380,000 ft2 Molex Little Rock facility to include a FDA registered manufacturing Center of Excellence for connected health and drug delivery devices.
This facility establishes a new manufacturing site in Little Rock, Arkansas for Phillips-Medisize’s medical business with capabilities for filling, drug handling, electronics and connected devices.
The construction of purpose-built cleanroom suites, as well as FDA registration and ISO 13485 certification are scheduled to be complete for its first customer’s production beginning in Q2 2018.
The investment aims to combine the innovative solutions and knowledge of Molex’s existing electronics production operations with Phillips-Medisize’s proven platform of drug delivery and medical device expertise.
Matt Jennings, CEO and President of Phillips-Medisize, said: “Phillips-Medisize is excited to align with Molex on the transformation of the Little Rock facility, which will be a Center of Excellence for connected health and drug delivery devices and [will] manufacture products that fit in today’s world of innovative devices. This facility will also allow us to accommodate large programs requiring extensive assembly and moulding operations, in cleanroom and other controlled environments, within a compressed timeframe.”
Jennings added: “The facility will have a particular focus on mid- to high-volume diagnostics, medical device and drug delivery systems that integrate electronics and digital applications, and will provide us with the additional space needed to reach our growth objectives over the upcoming years.”
This will be the company’s sixth expansion in the past six years to support long-term growth of its medical contract manufacturing business.